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Abstract
Background: It’s well recognized that X-linked inhibitor of apoptosis (XIAP) was the most potent caspase inhibitor
and second mitochondria-derived activator of caspase (Smac) was the antagonist of XIAP. Experiments in vitro
identified that down regulation of XIAP expression or applying Smac mimics could sensitize breast cancer cells to
chemotherapeutics and promote apoptosis. However, expression status and biologic or prognostic significance of
XIAP/Smac in breast invasive ductal carcinoma (IDC) were not clear. The present study aimed to investigate
relationship among expression status of XIAP/Smac, apoptosis index (AI), clinicopathologic parameters and
prognosis in IDC.
Methods: Immunohistochemistry and TUNEL experiment were performed to detect expression of XIAP, Smac, ER,
PR, HER2 and AI in 102 cases of paraffin-embedded IDC samples respectively. Expression of XIAP/Smac were also
detected in limited 8 cases of fresh IDC specimens with Western blot.
Results: Positive ratio and immunoscore of XIAP was markedly higher than Smac in IDC (P < 0.0001). It was
noteworthy that 44 cases of IDC were positive in nuclear for XIAP, but none was for Smac. Expression status of
Smac was more prevalent in HER2 positive group than negative group (P < 0.0001) and AI was positively
correlated with HER2 protein expression (rs = 0.265, P = 0.017). The present study first revealed that XIAP positive
nuclear labeling (XIAP-N), but not cytoplasmic staining (XIAP-C), was the apoptotic marker correlated significantly
with patients’ shortened overall survival (P = 0.039). Survival analysis demonstrated that XIAP-N was a new
independent prognostic factor except for patient age and lymph node status.
Conclusion: Disturbed balance of expression between XIAP and Smac probably contributed to carcinogenesis and
XIAP positive nuclear labeling was a new independent prognostic biomarker of breast IDC.
Keywords: XIAP nuclear labeling, Smac, apoptosis index, prognosis
Background
Disequilibration between cell proliferation and apoptosis
has been identified for a momentous mechanism of
tumorigenesis. Balance between expression status of
anti-apoptotic and pro-apoptotic proteins determines
cells to be alive or not. The key event of apoptosis
occurrence is cascade activation of caspases, and inhibi-
tor of apoptosis proteins (IAPs) play a important role in
caspase inhibition. It is well recognized that XIAP is the
most potent caspase inhibitor and Smac is one of the
antagonists of XIAP. Unbalanced expression between
XIAP and Smac probably contributes to progression of
renal cell carcinomas and results in marked apoptosis
resistance of this tumour[1]. Breast cancer is the most
common malignant tumour of female and estimated
new cases in America are 192,370 in 2010[2]. Previous
experiments in vitro have identified that sustained over-
expression of XIAP can cause acquired tumor necrosis
factor-alpha related apoptosis-inducing ligand (TRAIL)
resistance in MDA-231 human breast cancer cell[3].
Down regulation of XIAP expression or applying exo-
genous Smac mimics can sensitize tumor cells, especially
for breast cancer cells, to chemotherapeutics and
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any medium, provided the original work is properly cited.promote apoptosis[4-12]. IDC, not otherwise specified, is
the most frequent histological subtype of breast cancer.
However, expression status and biologic or prognostic
significance of XIAP/Smac proteins in breast IDC are
not clear. Immunohistochemistry and western blot are
performed to detect expression of XIAP/Smac and
terminal TdT-mediated dUTP nick-end labeling
(TUNEL) method is performed to detect AI in IDC in
the present study. And then, relationship among expres-
sion status of those proteins, AI, clinicopathologic para-
meters and prognosis is analyzed.
Materials and methods
Patients and Tissue samples
This study was done with IRB approval and all patients’
consent. Formalin-fixed, paraffin-embedded 102 cases of
consecutive IDC samples with different grades and
stages (Table 1) were obtained from patients who had
received modified radical mastectomy in the authors’
institution. The haematoxylin-eosin staining sections
had been checked by two experienced pathologists
before experiment. All of the patients were not adminis-
tered any treatment before operation and received post-
operative chemotherapeutics (Paclitaxel + Adriamycin +
Cyclophosphamide) for 15 consecutive weeks. And 9
out of the 102 patients still received radiotherapy in
addition. Limited 8 cases of fresh IDC specimens were
obtained from Laboratory of Pathology of West China
Hospital.
Antibodies
The following antibodies at indicated dilutions were
used in our study: XIAP (rabbit polyclonal, ABZOOM,
USA, 1:100 for IHC, and 1:1000 for immunoblotting),
Smac (mouse monoclonal, Cell Signaling, USA, 1:100
for IHC, and 1:1000 for immunoblotting), ER and PR
(rabbit monoclonal, MAIXIN, Fujian, China), HER2
(mouse monoclonal, MAIXIN, Fujian, China), GAPDH
(mouse monoclonal, clone 6C5, Kangcheng, Shanghai,
China, 1:10000 for immunoblotting).
Immunohistochemistry
Sections (4 μm) were immunostained by standard SP
method protocol. H2O2 (0.3%) was employed to block
endogenous peroxydase-binding activity. Antigen retrie-
val was by microwave boiling in citrate buffer (pH 6.0)
for 12 min. Omission of primary antibodies was used as
a blank control. Human normal skeletal muscle and
adenocarcinoma of stomach tissue sections were immu-
nostained as positive control for XIAP and Smac antibo-
dies respectively. Immunostaining was evaluated and
scored by two experienced pathologists independently.
All the staining was scored in epithelial cells, but not in
stromal cells or inflammatory cells. Cytoplasmic staining
of XIAP/Smac and HER2 showed a diffuse staining pat-
tern when positive and was scored by conventional
four-tiered semiquantitative scoring system (scores 0-3
for negative, weak, moderate, and strong staining,
respectively) based on staining intensity[13]. XIAP was
detected in nucleus and cytoplasm, and these results
were scored as XIAP-N and XIAP-C separately. The
staining of hormone receptor markers ER and PR was
exclusively in nucleus. It was assessed as positive that
more than 10% tumor cells showed brown nucleus dur-
ing ER, PR and XIAP-N immunostaining.
Western Blot Analysis
Fresh frozen tissue samples were minced and grinded
down to powder with mortar and pestle on liquid nitro-
gen. Total proteins from powdered tissue samples were
extracted in the presence of protease inhibitor cocktails
(Roche Diagnostics, Mannheim, Germany), quantitated
by using the BCA kit (Pierce Biotechnology Inc., Rock-
ford, IL, USA) and resolved by 10% SDS polyacrylamide
(Sigma, St Louis, MO, USA) gel electrophoresis. Pro-
teins were electroblotted to PVDF membrane (Amer-
sham Biosciences UK Ltd., Little Chalfont, UK) in CAPS
buffer (pH 11.0) (Amresco, Solon, OH, USA), and then
incubated with block solution (5% non-fat milk, 0.1%
Tween 20, in 1×TBS, Sigma, St Louis, MO, USA) at
room temperature for 2 h. Anti-GAPDH was used as
internal control. Horseradish peroxidase-labeled second-
ary antibodies were from Zymed (San Francisco, CA,
USA). Incubation with primary and secondary antibo-
dies were at room temperature for 2 h and 1.5 h,
respectively. Signals were detected by exposure to X-ray
films after treatment with the Super Signal enhanced
chemiluminescence kit (Pierce Biotechnology Inc., Rock-
ford, IL, USA) after incubation with primary and sec-
ondary antibodies.
TUNEL assay
Apoptotic tumor cells were detected with TUNEL
method, using an in situ cell death detection kit (Roche
Diagnostics, Mannheim, Germany). The assay was per-
formed according to the manufacturer’si n s t r u c t i o n s .
Briefly, after routine deparaffinization and treatment
with H2O2 (3%), sections were digested with proteinase
Table 1 Pathological staging and grading of 102 cases of
invasive ductal carcinoma
staging grading
pT1 19(18.6%) G1 25(24.5%)
pT2 57(55.9%) G2 50(49.0%)
pT3 24(23.5%) G3 27(26.5%)
pT4 2(2.0%)
Total 102(100%) 102(100%)
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with the reaction mixture (1:40, 60 min) at 37°C. Incor-
porated fluorescein was detected with horseradish per-
oxidase after a 30 min incubation at 37°C and
subsequent dyed with DAB. Brown nucleus was assessed
as positive apoptotic cell and counted for 1000 tumor
cells, scoring as AI in one section for at least 10 high
power fields.
Statistical Analysis
General statistical and survival analysis were carried out
with the statistical software package SPSS 17.0 (SPSS,
Chicago, USA). Intergroup differences were examined
by using x
2 test, independent example t-test and Mann-
Whitney U-test. A P -value of less than 0.05 was consid-
ered to indicate the statistical significance.
Results
Relationship among expression status of XIAP/Smac
detected by immunohistochemistry, clinicopathologic
parameters and biomarkers
B o t hX I A Pa n dS m a cw e r ep o s i t i v ei nc y t o p l a s mo f
tumor cells with strong or moderate intensity, respec-
tively (Figure 1, 2). The positive ratio of XIAP (84.3%, 86/
102) was more higher than that of Smac (33.3%, 34/102),
and immunoscore of XIAP was higher than Smac in IDC
too (P < 0.0001). It was noteworthy that 44 IDC samples
were nuclear positive for XIAP (Figure 3), but none was
for Smac. And cytoplasm positive status of XIAP nuclear
positive group was stronger than the negative group (P =
0.030, 0.047) (Table 2, 3). Otherwise, Smac immunoscore
was prevalent in HER2 positive group than negative
group (P < 0.0001). Remaining data revealed that the
expression status of XIAP/Smac was not correlated with
patient age, tumor size, lymph node status, histologic
grading, expression of ER and PR (Table 2, 3).
Western Blot detection of XIAP/Smac protein expression
In limited 8 cases of fresh IDC examples, we detected
expression of both XIAP/Smac protein and GAPDH
internal control (Figure 4). The semi-quantitation analy-
sis data indicated that expression status of XIAP protein
was more stronger than Smac in fresh IDC specimens
with ImageQuant software (Data wasn’t shown.).
Relationship among apoptosis index, clinicopathologic
parameters and biomarkers
The positive apoptotic tumor cells showed brown
nucleus in TUNEL detection (Figure 5). AI of total 102
Figure 1 Higher power view of representative cytoplasmic
immunostaining of XIAP in IDC. Original magnification for this
figure: ×400.
Figure 2 Higher power view of representative cytoplasmic
immunostaining of Smac in IDC. Original magnification for this
figure: ×400.
Figure 3 Higher power view of representative nuclear
immunostaining of XIAP, in addition to cytoplasmic staining in
IDC. Original magnification for this figure: ×400.
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1.322 ± 1.052). The correlation analysis revealed that AI
was positively correlated with HER2 protein expression
(rs = 0.265, P = 0.017), but not correlated with patient
age, tumor size, lymph node status, histologic grading
and expression of XIAP, Smac, ER and PR (Data wasn’t
shown.).
Relationship among expression status of XIAP/Smac,
apoptosis index, clinicopathologic parameters and
prognosis in IDC
We further analyzed the prognostic value of XIAP-N,
XIAP-C, Smac, HER2, ER, PR, AI, patient age, lymph
node status and histologic grading in this cohort of 102
pathologically confirmed breast IDC patients, who
received modified radical mastectomy, postoperative
chemotherapeutics or radiotherapy. The median follow-
up time for all patients was 60.0 months. In this cohort,
27 patients died of recurrence or metastases, and
another three patients who had been pathologically con-
firmed recurrence were alive. Kaplan-Meier method and
log rank test were used for univariate analysis of overall
survival and Cox proportional hazard regression was
used for multivariate analysis. Univariate analyses
revealed that XIAP-N (positive vs negative), patient age
(<50 years vs ≥50 years), tumor size (<5 cm vs ≥5c m )
and lymph node status (N0 vs N1-3) had prognostic sig-
nificance (Figure 6, 7, 8 and 9). However, in multivariate
analysis incorporating these parameters, only XIAP-N,
patient age and lymph node status retained independent
prognostic power, with approximately 3.0-, 9.2- to 14.8-
fold increase of risk for disease-specific death respec-
tively (Table 4).
Discussion
XIAP was the most potent caspase inhibitor, whose
molecular structure was known best in IAP family[14].
There were three important components in XIAP gene
structure, including BIR domain, Linker domain and
Ring-figure domain which possesed the activity as ubi-
quitin ligase E3, and XIAP could bind to caspase-3, 7, 9
directly to inhibit their activity[15]. Expression of XIAP
protein had been detected in most of carcinoma cells,
and overexpression of this protein was correlated with
patients’sensitivity to anticancer drugs and prognosis
[16]. For instance, overexpression of XIAP and Survivin,
Table 2 Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables
n* XIAP-C Smac XIAP-N
PR P value PR P value PR P value
Age
<50 49 42(85.7%) 20(40.8%) 21(42.9%)
≥50 53 0.789 0.145 1.000
Size 44(83.0%) 14(26.4%) 23(43.4%)
≤5 cm 77 67(87.0%) 26(33.8%) 33(42.9%)
>5 cm 25 19(76.0%) 0.212 8(32.0%) 1.000 11(44.0%) 1.000
LN status
N0 39 33(84.6%) 14(35.9%) 14(35.9%)
N1-3 63 53(84.1%) 1.000 20(31.7%) 0.672 30(47.6%) 0.305
Grade
I 25 22(88.0%) 10(40.0%) 13(52.0%)
II-III 77 64(83.1%) 0.755 24(31.2%) 0.468 31(40.3%) 0.356
ER
positive 39 31(79.5%) 14(35.9%) 20(51.3%)
negative 63 55(87.3%) 0.401 20(31.7%) 0.672 24(38.1%) 0.221
PR
positive 44 36(81.8%) 18(40.9%) 23(52.3%)
negative 58 50(86.2%) 0.591 16(27.6%) 0.204 21(36.2%) 0.112
HER2
positive 94 78(83.0%) 34(36.2%) 41(43.6%)
negative 8 8(100.0%) 0.351 0(0.0%) 0.049 3(37.5%) 1.000
XIAP-N
positive 44 41(93.2%) 16(36.4%) /
negative 58 44(75.9%) 0.030 18(31.0%) 0.672 /
n*: number of cases. PR: positive rate. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively.
P-values (two sided) < 0.05 were highlighted in bold.
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tance to Adriamycin, Paclitaxel and Vincristine in sev-
eral kinds of breast cancer cell[17,18]. In LNCaP
prostate cancer cells, XIAP restrained apoptosis induced
by Paclitaxel through cutting down activity of caspase-3
and inhibiting processing of pro-caspase-3 moreover
[19]. On the contrary, patients of acute myeloid leukae-
mia with low expression level of XIAP could get more
favorite prognosis[16].
Smac, which was named by direct IAP-binding protein
with low pI (DIABLO) too, was one of the two known
negative regulators of XIAP presently. Smac promoted
apoptosis through several ways, including firstly inter-
acting with cytochrome c/Apaf-1/pro-caspase-9 complex
to activate caspase-9 or downstream effector molecule
caspase-3[20,21], secondly binding to BIR domain of
XIAP competively and blocking it’s inhibitory effect on
caspases[22], and lastly cooperating with Omi/HtrA2 to
promote XIAP to degradation[23,24]. Previous study
reported that total positive ratio of Smac was 62% in
several carcinomas, and lack of Smac would lead to
down regulation of apoptosis[25].
Preliminary research showed positive ratio of XIAP in
breast cancer were 89.7%, but no related report about
Smac[26]. Our data indicated not only positive ratio but
a l s oi m m u n o s c o r eo fX I A Pw e r em o r eh i g h e rt h a n
Smac in breast IDC, and semi-quantitation analysis of
western blot detection proved it too. But it just could be
regarded as a attempt because the fresh samples were so
limited in this study. Disturbed balance of expression
between XIAP and Smac contributed to progression of
renal cell carcinoma and XIAP was an independent
prognostic biomarker of clear cell renal cell carcinoma
[1,27]. Similarly, it also could be believed that disturbed
balance of expression between XIAP and Smac contrib-
uted to carcinogenesis of IDC based on results of the
present study. A set of data, consisting with other
report, showed that expression status of XIAP/Smac was
not correlated with patient age, tumor size, lymph node
status, histologic grading, expression of ER and PR[26].
Whereas, Jaffer and his colleagues found a possible role
of XIAP in the more aggressive clinical behavior of
grade 3, compared with lower-grade ductal carcinomas
[28]. These conflicting results need be confirmed in a
following large sample study.
In previous reports, XIAP was only detected in cyto-
plasm[26,28]. However, we found 44 IDC samples were
positive in nucleus and cytoplasm for XIAP
Table 3 Relationship analysis among XIAP/Smac immunoscore, apoptosis index, and clinicopathologic variables
n* XIAP P value Smac P value AI P value
Age
<50 49 2.3 ± 0.8 0.5 ± 0.6 1.3 ± 1.0
≥50 53 2.4 ± 0.8 0.586 0.3 ± 0.5 0.124 1.3 ± 1.1 0.903
Size
≤5 cm 77 2.4 ± 0.8 0.4 ± 0.6 1.3 ± 1.1
>5 cm 25 2.2 ± 0.9 0.386 0.4 ± 0.7 0.880 1.4 ± 1.0 0.849
LN status
N0 39 2.4 ± 0.8 0.4 ± 0.6 1.2 ± 0.8
N1-3 63 2.4 ± 0.8 0.969 0.4 ± 0.6 0.958 1.4 ± 1.2 0.282
Grade
I 25 2.5 ± 0.7 0.5 ± 0.6 1.6 ± 1.4
II-III 77 2.3 ± 0.8 0.444 0.4 ± 0.6 0.555 1.2 ± 0.9 0.227
ER
positive 39 2.3 ± 0.8 0.4 ± 0.6 1.2 ± 1.2
negative 63 2.4 ± 0.8 0.376 0.4 ± 0.6 0.659 1.4 ± 1.0 0.463
PR
positive 44 2.3 ± 0.8 0.5 ± 0.6 1.3 ± 0.8
negative 58 2.4 ± 0.8 0.669 0.3 ± 0.6 0.319 1.4 ± 1.2 0.779
HER2
positive 94 2.4 ± 0.8 0.4 ± 0.6 1.3 ± 0.9
negative 8 2.2 ± 0.8 0.544 0.0 ± 0.6 <0.0001 1.8 ± 2.1 0.611
XIAP-N
positive 44 2.6 ± 0.6 0.4 ± 0.6 1.3 ± 1.1
negative 58 2.2 ± 0.9 0.047 0.3 ± 0.6 0.540 1.4 ± 1.0 0.630
n*: number of cases. AI: apoptosis index. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP,
respectively. P-values (two sided) < 0.05 were highlighted in bold.
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was maybe caused by using different primary antibodies
and tissue specimens from different race. Tissue speci-
mens in present study were all from Chinese female
patients, but not from Europe or America. Something
different from previous reports was that XIAP nuclear
labeling (XIAP-N), but not cytoplasmic staining of XIAP
(XIAP-C), was the apoptotic marker which correlated
significantly with IDC patients’ shortened overall survi-
val. Univariate survival analysis disclosed that patient
age, tumor size, lymph node status and XIAP-N had
prognostic significance. Nevertheless, it was demon-
strated by multivariate survival analysis that only patient
age, lymph node status and XIAP-N were independent
prognostic factors.
It had been introduced previously that XIAP and Sur-
vivin, two important caspase inhibitors of IAP family,
were comitantly overexpressing in several kinds of
breast cancer cell and oweing to elevated resistance to
chemotherapeutics[17,18]. Even more, Survivin was an
independent predictor of short-term survival in poor
prognostic breast cancer patients[26]. All results stated
above called attention to us that overexpression of XIAP
and Survivin were significantly correlated with carcino-
genesis, progression and prognosis of breast cancer, and
the two molecules played similar role in several aspects
in breast cancer. Therefore, we concluded XIAP, like
Survivin, probably was a new independent prognostic
biomarker of breast cancer although it was different that
Figure 4 XIAP and Smac proteins in IDC (T1-T8) assessed by
Western blot analysis. GAPDH served as internal control of protein
loading. Expression of XIAP was more stronger than Smac in IDC
with semi-quantitation analysis.
Figure 5 Representative positive apoptotic tumor cells in IDC
by TUNEL detection. Original magnification for this figure: ×400.
Figure 6 Kaplan-Meier comparison result showed that XIAP-N
was correlated significantly with IDC patients’ shortened
overall survival. Log rank test P-value (two sided) was listed in the
figure.
Figure 7 Kaplan-Meier comparison result showed that patient
age (≥50 years) was correlated significantly with IDC patients’
shortened overall survival. Log rank test P-value (two sided) was
listed in the figure.
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had prognostic significance. This condition was similar
to previous reports that Survivin nuclear labeling was a
prognostic biomarker of breast cancer and superficial
urothelial carcinoma of urinary bladder[29,30].
There was another interesting result in our study
that immunoscore of Smac was prevalent in HER2
positive group than negative group, and apoptosis
index was positively correlated with HER2 protein
expression. Someone believed that apoptosis was
decreasing in malignant tumors. But in fact, increasing
apoptotic tumor cells could usually be found in malig-
nancies, especially for tumors with high proliferating
Figure 8 Kaplan-Meier comparison result showed that tumor
size (>5 cm) was correlated significantly with IDC patients’
shortened overall survival. Log rank test P-value (two sided) was
listed in the figure.
Figure 9 Kaplan-Meier comparison result showed that lymph
node status was correlated significantly with IDC patients’
shortened overall survival. Log rank test P-value (two sided) was
listed in the figure.
Table 4 Relationship analysis among XIAP/Smac
expression, apoptosis index, clinicopathologic
parameters and prognosis
n* P value P value RR 95%CI
(Log rank) (Cox-reg) Lower Upper
Age
<50 49
≥50 53 <0.0001 0.002 9.181 2.332~36.147
Size
≤5c m 7 7
>5 cm 25 0.006 0.065 2.903 0.935~9.016
LN status
N0 39
N1-3 63 <0.0001 0.012 14.757 1.803~120.750
Grade
I2 5
II-III 77 0.596 0.391 0.555 0.144~2.134
XIAP-C
<2 16
≥2 86 0.153 0.188 0.398 0.101~1.568
XIAP-N
positive 44
negative 58 0.039 0.043 3.027 1.033~8.869
Smac
<2 68
≥2 34 0.595 0.395 0.634 0.222~1.809
ER
positive 39
negative 63 0.965 0.774 1.181 0.379~3.681
PR
positive 44
negative 58 0.861 0.779 1.177 0.378~3.662
HER2
<2 31
≥2 71 0.182 0.082 3.522 0.853~14.538
AI
<1.32 65
≥1.32 37 0.648 0.658 1.244 0.474~3.264
n*: number of cases. RR: relative risk. CI: confidence interval. LN: lymph node.
AI: apoptosis index. XIAP-C and XIAP-N denoted cytoplasmic immune staining
score and nuclear labeling of XIAP, respectively. P-values (two sided) < 0.05
were highlighted in bold.
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HER2 contributed to breast carcinogenesis. So, it’sn o t
difficult for us to understand that apoptosis index was
positively correlated with HER2 protein expression in
our study. Our result also consisted with Hinnis’ study
that AI was not correlated with patient age, tumor
size, lymph node status, histologic grading and expres-
sion of XIAP, Smac, ER and PR protein[26]. At the
same time, our following up data revealed similar
result with previous reports that AI was not correlated
with IDC patients’ prognosis[31,32]. However, why
there was prevalent Smac in oncogene HER2 positive
group? The relationship between the two parameters
had not been reported before, and both mechanism
and significance were not clear too. Maybe, this point
would be a new target for us to perform a large sample
study in the future.
As discussed above, XIAP was a potent protein for
apoptosis inhibition and Smac was an important nega-
tive regulator of the former. Disturbed balance of
expression between XIAP and Smac probably contribu-
ted to carcinogenesis and XIAP positive nuclear labeling
was a sign of unfavourable prognosis in breast invasive
ductal carcinoma. It was important for us to demon-
strate the XIAP nuclear staining is genuine, and we
were going to practice it in breast cancer cell lines in
following study. Further more, Relationship among
Smac, HER2 and apoptosis index would be explored in
the following study too.
Conclusion
Disturbed balance of expression between XIAP and
Smac probably contributed to carcinogenesis and XIAP-
N was a new independent prognostic biomarker of
breast invasive ductal carcinoma.
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